Personal Wealth Partners purchased a new position in Zimmer Biomet Holdings Inc (NYSE:ZBH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 218 shares of the medical equipment provider’s stock, valued at approximately $26,000.
Other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its stake in shares of Zimmer Biomet by 207.6% in the first quarter. Lindbrook Capital LLC now owns 203 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 137 shares in the last quarter. Motco lifted its stake in shares of Zimmer Biomet by 86.2% in the first quarter. Motco now owns 216 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 100 shares in the last quarter. Private Ocean LLC lifted its stake in shares of Zimmer Biomet by 34.8% in the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 80 shares in the last quarter. Horan Capital Advisors LLC. bought a new position in shares of Zimmer Biomet in the first quarter valued at $51,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Zimmer Biomet in the first quarter valued at $54,000. Institutional investors and hedge funds own 88.57% of the company’s stock.
ZBH has been the topic of a number of recent research reports. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c” rating in a research note on Friday, June 7th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. Citigroup raised their price target on shares of Zimmer Biomet from $146.00 to $158.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. ValuEngine raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, July 27th. Finally, Wells Fargo & Co raised their price target on shares of Zimmer Biomet from $143.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet currently has a consensus rating of “Buy” and an average price target of $140.64.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 EPS for the quarter, topping the consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.92 earnings per share. As a group, sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.69%. The ex-dividend date was Thursday, June 27th. Zimmer Biomet’s dividend payout ratio is 12.57%.
In other Zimmer Biomet news, insider Sang Yi sold 426 shares of Zimmer Biomet stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $114.88, for a total value of $48,938.88. Following the sale, the insider now owns 1,457 shares of the company’s stock, valued at $167,380.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.72% of the company’s stock.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
See Also: Support Level
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.